RecruitingNCT06058182

RNA as Prognostic Biomarkers in Patients With Acute Coronary Syndrome

Sponsor

IRCCS Policlinico S. Donato

Enrollment

70 participants

Start Date

Jul 13, 2020

Study Type

OBSERVATIONAL

Conditions

Coronary Syndrome

Summary

Identify circulating protein-coding (mRNAs) or non-coding (ncRNAs) transcripts (ACS\_signature) predictive of ventricular dysfunction in ACS patients undergoing PCI.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Age >18 years
Patients with ACS (first episode), defined according to the guidelines of the European Society of Cardiology (ESC) 2017
Indication for percutaneous revascularization treatment
Informed consent to study enrollment

Exclusion Criteria20

Severe valve disease or other conditions requiring cardiac surgery
Previous cardiac surgery including coronary artery bypass grafts
Total chronic occlusions
Patients with known hypersensitivity or contraindication to any of the following drugs:
heparin
aspirin,
clopidogrel,
ticlopidine,
sirolimus,
everolimus.
Any contraindication to drug-eluting stent implantation (DES)
Patients with a documented history of myocardial infarction;
Left ventricular ejection fraction (LVEF) <30% before PCI
Patients in cardiogenic shock
Patients with advanced ST-segment elevation myocardial infarction (> 48 h from onset of symptoms/Q waves on electrocardiogram) or undergoing fibrinolysis;
Patients with prior known cardiomyopathy with LVEF < 40%
Patients with malignant neoplasm or systemic disease with quoad vitam prognosis less than 1 year;
Patients with known active infectious diseases;
Patients who are unable to express valid informed consent to the act of enlistment
Pregnant women